BR0314552A - Métodos para prognosticar elevações de colesterol durante terapia imunossupressora - Google Patents

Métodos para prognosticar elevações de colesterol durante terapia imunossupressora

Info

Publication number
BR0314552A
BR0314552A BR0314552-2A BR0314552A BR0314552A BR 0314552 A BR0314552 A BR 0314552A BR 0314552 A BR0314552 A BR 0314552A BR 0314552 A BR0314552 A BR 0314552A
Authority
BR
Brazil
Prior art keywords
methods
predict
immunosuppressive therapy
elevations during
cholesterol
Prior art date
Application number
BR0314552-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Sridhar Kudaravalli
Mihael Hristos Polymeropoulos
Rosarelis Torres
Curt Douglas Wolfgang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314552(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0314552A publication Critical patent/BR0314552A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR0314552-2A 2002-09-30 2003-09-29 Métodos para prognosticar elevações de colesterol durante terapia imunossupressora BR0314552A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41512302P 2002-09-30 2002-09-30
PCT/EP2003/010798 WO2004029618A2 (en) 2002-09-30 2003-09-29 Methods to predict cholesterol elevations during immunosuppressant therapy

Publications (1)

Publication Number Publication Date
BR0314552A true BR0314552A (pt) 2005-08-09

Family

ID=32043422

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314552-2A BR0314552A (pt) 2002-09-30 2003-09-29 Métodos para prognosticar elevações de colesterol durante terapia imunossupressora

Country Status (13)

Country Link
US (2) US7732134B2 (enExample)
EP (1) EP1549770B1 (enExample)
JP (1) JP4575775B2 (enExample)
CN (1) CN100453650C (enExample)
AT (1) ATE389034T1 (enExample)
AU (1) AU2003287955B2 (enExample)
BR (1) BR0314552A (enExample)
CA (1) CA2500979A1 (enExample)
DE (1) DE60319719T2 (enExample)
ES (1) ES2302959T3 (enExample)
IL (1) IL167639A (enExample)
PT (1) PT1549770E (enExample)
WO (1) WO2004029618A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611021A2 (pt) * 2005-05-31 2010-08-10 Novartis Ag combinação de inibidores de hmg-coa redutase e inibidores de mtor
HUE052213T2 (hu) 2009-11-06 2021-04-28 Univ Leland Stanford Junior Grafitkilökõdés nem invazív diagnosztizálása szervátültetett betegekben
US20130005822A1 (en) * 2010-03-15 2013-01-03 Rubin Bruce K Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686246A (en) * 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
CN1753903B (zh) * 2001-11-19 2010-05-12 白介素遗传公司 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性

Also Published As

Publication number Publication date
JP4575775B2 (ja) 2010-11-04
CN100453650C (zh) 2009-01-21
ES2302959T3 (es) 2008-08-01
DE60319719T2 (de) 2009-03-12
HK1084445A1 (zh) 2006-07-28
US7732134B2 (en) 2010-06-08
EP1549770B1 (en) 2008-03-12
WO2004029618A2 (en) 2004-04-08
AU2003287955A1 (en) 2004-04-19
JP2006500930A (ja) 2006-01-12
AU2003287955B9 (en) 2004-04-19
CA2500979A1 (en) 2004-04-08
ATE389034T1 (de) 2008-03-15
US20100184798A1 (en) 2010-07-22
US20060246439A1 (en) 2006-11-02
CN1685062A (zh) 2005-10-19
DE60319719D1 (de) 2008-04-24
WO2004029618A3 (en) 2004-06-17
IL167639A (en) 2011-10-31
EP1549770A2 (en) 2005-07-06
AU2003287955B2 (en) 2007-06-21
PT1549770E (pt) 2008-06-24

Similar Documents

Publication Publication Date Title
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
PL374865A1 (en) Treatment of tnf alpha related disorders
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
TNSN05300A1 (en) Treatment with anti-vegf antibodies
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
PT1427409E (pt) Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
BR0214821A (pt) Métodos de tratamento da psicose e esquizofrenia com base nos polimorfismos no gene cntf
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
PT1549770E (pt) Métodos para prever aumentos de colesterol durante terapia imunossupressora
PT1604211E (pt) Identificação de compostos terapêuticos
TR200200278T2 (tr) Kalsilitik bileşimler
EA200601871A1 (ru) Способы лечения аутоиммунных и воспалительных заболеваний
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
NO20005548L (no) Mykobakterieinhibitorer
DE602005021681D1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
BR0113646A (pt) Tratamento de distúrbios inflamatórios

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2273 DE 29/07/2014.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.